Trials / Unknown
UnknownNCT06265311
IDUS in CBD Stone Recurrence High Risk Patients
Practical Value of IDUS in Patients With High Risk of Recurrence of Common Bile Duct Stones After ERCP Lithotomy
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Shanghai Municipal Hospital of Traditional Chinese Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to observed CBD stones cases with high recurrence risks applying IDUS or not during ERCP. Patients with CBD stone high recurrence risks were enrolled in this study, and prospectively randomized into IUDS group and control group during lithotomy. Operation time, radiation time, hospitalization cost, retain of nasobiliary tube, deployment of stent were recorded. Symptoms and conditions after ERCP were also followed up including blood amylase, routine blood test, abdominal pain, post-ERCP pancreatitis, resection of gallbladder, recurrence of CBD stone and onset of cholangitis.
Detailed description
Patients with CBD stone high recurrence risks were enrolled in this study, and prospectively randomized into IUDS group and control group during lithotomy. High risks were defined as diameter of CBD\>1.5cm, number of calculi\>2, and lithotripsy. Operation time, radiation time, hospitalization cost, retain of nasobiliary tube, deployment of stent were recorded. Symptoms and conditions after ERCP were also followed up including blood amylase, routine blood test, abdominal pain, post-ERCP pancreatitis, resection of gallbladder, recurrence of CBD stone and onset of cholangitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | IDUS examination | for patients with high risks of bile duct stones recurrence using IDUS during ERCP |
Timeline
- Start date
- 2021-11-02
- Primary completion
- 2024-01-31
- Completion
- 2024-06-01
- First posted
- 2024-02-20
- Last updated
- 2024-04-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06265311. Inclusion in this directory is not an endorsement.